SCHEMBL26026941

SCHEMBL26026941

CC(C)[C@H](NC(=O)CCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])C(=O)N[C@@H](CCCCNN)C(=O)Nc1ccc(O[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ FURIN P09958 11/20 0.35
▸ ROCK2 O75116 1/20 0.31
▸ CTSL P07711 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25362246 0.91 FURIN (0.36) FURINROCK2CTSL
SCHEMBL25362237 0.91 FURIN (0.36) FURINROCK2CTSL
SCHEMBL25361974 0.89 FURIN (0.34) FURIN
SCHEMBL25361983 0.89 FURIN (0.34) FURIN
SCHEMBL26026944 0.88 SIRT5 (0.38) FURINROCK2CTSL
SCHEMBL26027087 0.86 FURIN (0.40) FURINROCK2CTSL
SCHEMBL26027085 0.86 KLKB1 (0.43) FURINROCK2CTSL
SCHEMBL25438103 0.80 CTSL (0.41) FURINROCK2CTSL
SCHEMBL25359008 0.80 CTSL (0.38) FURINROCK2CTSL
SCHEMBL24390287 0.80 FURIN (0.38) FURINROCK2CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP FURIN 2087/4885ROCK2 2442/4885CTSL 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback